心力衰竭与心房颤动共存的流行病学和相关临床研究进展

金雪娟; 周京敏

doi:10.13201/j.issn.1001-1439.2019.03.002

心力衰竭与心房颤动共存的流行病学和相关临床研究进展

金雪娟^1,2, ,,
周京敏¹

- 1. 复旦大学附属中山医院上海市心血管病研究所(上海, 200032);
- 2. 复旦大学循证医学中心
基金项目:
国家科技支撑计划（No：2011BAI11B00）

详细信息

通讯作者: 金雪娟,E-mail:xjin26@hotmail.com

中图分类号: R541.6

收稿日期: 2019-01-05

The coexistence of heart failure and atrial fibrillation: progress in Epidemiology and related clinical research

JIN Xuejuan^1,2, ,,
ZHOU Jingmin¹

- 1. Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai, 200032, China;
- 2. Evidence-Based Medicine Center, Fudan University

More Information

Corresponding author: JIN Xuejuan, E-mail: xjin26@hotmail.com

Received Date: 05 January 2019

摘要

摘要: 心房颤动（atrial fibrillation，AF）和心力衰竭（heart failure，HF）经常共存，HF的两种亚型——射血分数保留型HF （HF with preserved ejection fraction，HFpEF）与射血分数降低型HF （HF with reduced ejection fraction，HFrEF）均在AF发生发展中起重要作用，互为因果，共同导致不良预后。从预防性研究看，许多研究集中于AF患者的卒中预防，但几乎没有研究关注在AF患者中HF的预测和预防。从治疗性研究看，药物治疗对AF与HF共存预后产生影响的证据非常有限，许多证据来自于观察性研究或者亚组分析的研究，或者有方法学缺陷的事后分析结果，需要谨慎解读。导管消融可降低HFrEF合并AF患者的死亡风险，然而对于HFpEF与AF并存的患者尚无研究证据。目前，亟需进行充分的头对头随机对照临床试验，以明确AF和HF之间复杂的相互关系，以期得到最佳预防与治疗措施。
- 心力衰竭 /
- 心房颤动 /
- 流行病学 /
- 临床研究
Abstract: Atrial fibrillation(AF) and heart failure(HF) commonly coexist.Both HF with preserved ejection fraction(HFpEF) and HF with reduced ejection fraction(HFrEF) have complex mutual cause-and-effect interactions in the development of AF, and their co-presence is associated with adverse outcomes.Currently, many clinical studies have focused more on stroke prevention instead of HF prevention.Despite advances in medical therapy in HF and AF, there is still uncertainty on the best management on the co-presence of HF and AF.Moreover, and most of evidence on co-presence were from retrospective observational studies, subgroup analyses or post hoc analysis with methodological limitation.In surgical treatment, catheter ablation can reduce the risk of all cause mortality in patients with AF with HFrEF, but research evidence of the coexistence of HFpEF and AF is still limited.At present, there is an urgent need for a full head-to-head randomized controlled clinical trials to clarify the optimal prevention and treatment in the complex co-presence of AF and HF.
- heart failure /
- atrial fibrillation /
- Epidemiology /
- clinical research

HTML全文

参考文献(29)

[1]	Khan MA, Neyses L, Mamas MA.Atrial fibrillation in heart failure:an innocent bystander?[J].Curr Cardiol Rev, 2012, 8(4):273-280.
[2]	Schnabel RB, Yin X, Gona P, et al.50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study:a cohort study[J].Lancet, 2015, 386(9989):154-162.
[3]	戚玉勤, 金雪娟, 李双, 等.上海市社区老年人群心房颤动的流行病学特征及抗凝治疗现状调查[J].中国临床医学, 2018, 25(1):1-4.
[4]	McMurray JJ, Stewart S.Epidemiology, aetiology, and prognosis of heart failure[J].Heart, 2000, 83(5):596-602.
[5]	葛均波, 杨杰孚, 张健, 主编.中国心力衰竭防治现状蓝皮书·2015[M].北京:人民卫生出版社, 2016.
[6]	Benjamin EJ, Virani SS, Callaway CW, et al.Heart Disease and Stroke Statistics-2018 Update:A Report From the American Heart Association[J].Circulation, 2018, 137(12):e67-e492.
[7]	Santhanakrishnan R, Wang N, Larson MG, et al.Atrial Fibrillation Begets Heart Failure and Vice Versa:Temporal Associations and Differences in Preserved Versus Reduced Ejection Fraction[J].Circulation, 2016, 133(5):484-492.
[8]	Raunso J, Pedersen OD, Dominguez H, et al.Atrial fibrillation in heart failure is associated with an increased risk of death only in patients with ischaemic heart disease[J].Eur J Heart Fail, 2010, 12(7):692-697.
[9]	Wang TJ, Larson MG, Levy D, et al.Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality:the Framingham Heart Study[J].Circulation, 2003, 7(23):2920-2925.
[10]	Chamberlain AM, Redfield MM, Alonso A, et al.Atrial fibrillation and mortality in heart failure:a community study[J].Circulation Heart Fail, 2011, 4(6):740-746.
[11]	Pandey A, Kim S, Moore C, et al.Predictors and Prognostic Implications of Incident Heart Failure in Patients With Prevalent Atrial Fibrillation[J].JACC Heart Fail, 2017, 5(1):44-52.
[12]	Schneider MP, Hua TA, Bohm M, et al.Prevention of atrial fibrillation by renin-angiotensin system inhibition a meta-analysis[J].J Am Coll Cardiol, 2010, 55(21):2299-2307.
[13]	Ducharme A, Swedberg K, Pfeffer MA, et al.Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure:Assessment of Reduction in Mortality and morbidity (CHARM) program[J].Am Heart J, 2006, 152(1):86-92.
[14]	Joglar JA, Acusta AP, Shusterman NH, et al.Effect of carvedilol on survival and hemodynamics in patients with atrial fibrillation and left ventricular dysfunction:retrospective analysis of the US Carvedilol Heart Failure Trials Program[J].Am Heart J, 2001, 142(3):498-501.
[15]	Kotecha D, Holmes J, Krum H, et al.Beta-Blockers in Heart Failure Collaborative Group Efficacy of β blockers in patients with heart failure plus atrial fibrillation:an individual-patient data meta-analysis[J].Lancet, 2014, 384(9961):2235-2243.
[16]	Rienstra M, Damman K, Mulder BA, et al.Beta-blockers and outcome in heart failure and atrial fibrillation:a meta-analysis[J].JACC Heart Fail, 2013, 1(1):21-28.
[17]	Ahmed A, Rich MW, Love TE, et al.Digoxin and reduction in mortality and hospitalization in heart failure:a comprehensive post hoc analysis of the DIG trial[J].Eur Heart J, 2006, 27(2):178-186.
[18]	Vamos M, Erath JW, Benz AP, et al.Meta-Analysis of Effects of Digoxin on Survival in Patients with Atrial ibrillation or Heart Failure:An Update[J].Am J Cardiol, 2019, 123(1):69-74.
[19]	Roy D, Talajic M, Nattel S, et al.Rhythm control versus rate control for atrial fibrillation and heart failure[J].New Eng J Med, 2008, 358(25):2667-2677.
[20]	Hohnloser SH, Crijns HJ, van Eickels M, et al.Dronedarone in patients with congestive heart failure:insights from ATHENA[J].Eur Heart J, 2010, 31(14):1717-1721.
[21]	Kober L, Torp-Pedersen C, McMurray JJ, et al.Increased mortality after dronedarone therapy for severe heart failure[J].New Eng J Med, 2008, 358(25):2678-2687.
[22]	Olsson LG, Swedberg K, Ducharme A, et al.Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction:results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and Morbidity (CHARM) program[J].J Am Coll Cardiol, 2006, 47(10):1997-2004.
[23]	ACTIVE I Investigators, Yusuf S, Healey JS, et al.Irbesartan in patients with atrial fibrillation[J].N Engl J Med, 2011, 364(10):928-938.
[24]	O'Meara E, Khairy P, Blanchet MC, et al.Mineralocorticoid receptor antagonists and cardiovascular mortality in patients with atrial fibrillation and left ventricular dysfunction:insights from the Atrial Fibrillation and Congestive Heart Failure Trial[J].Circ Heart Fail, 2012, 5(5):586-593.
[25]	Agarwal M, Apostolakis S, Lane DA, et al.The impact of heart failure and left ventricular dysfunction in predicting stroke, thromboembolism, and mortality in atrial fibrillation patients:a systematic review[J].Clin Ther, 2014, 36(9):1135-1144.
[26]	Marrouche NF, Brachmann J, Andresen D, et al.Catheter ablation for atrial fibrillation with heart failure[J].N Engl J Med, 2018, 378(5):417-427.
[27]	Shantsila E, Haynes R, Calvert M, et al.IMproved exercise tolerance in patients with PReserved Ejection fraction by Spironolactone on myocardial fibrosiS in Atrial Fibrillation rationale and design of the IMPRESS-AF randomised controlled trial[J].BMJ Open, 2016, 6(10):e012241.
[28]	Kotecha D, Banerjee A, Lip GY.Increased stroke risk in atrial fibrillation patients with heart failure:does ejection fraction matter?[J].Stroke, 2015, 46(3):608-609.
[29]	Mamas MA, Caldwell JC, Chacko S, et al.A meta-analysis of the prognostic significance of atrial fibrillation in chronic heart failure[J].Eur J Heart Fail, 2009, 11(7):676-683.